Incidence of Cardiovascular Events in Which 2 Thiazolidinediones Are Used as Add-on Treatments for Type 2 Diabetes Mellitus in a Taiwanese Population

Clinical Therapeutics

Volumn 33, Issue 12, 2011, Pages 1904-1913

  Chou, Chih Chieh ^a   Chen, Wei Liang ^a   Kao, Tung Wei ^a   Chang, Yaw Wen ^a   Loh, Ching Hui ^a   Wang, Chung Ching ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cardiovascular disease; Diabetes; Pioglitazone; Rosiglitazone; Thiazolidinedione

Indexed keywords

ANTIHYPERTENSIVE AGENT; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE; ROSIGLITAZONE;

ADOLESCENT; ADULT; AGED; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHILD; CONGESTIVE HEART FAILURE; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL; TAIWAN; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 83455210425     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.025     Document Type: Article

References (43)

1. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14.
2. Chang C., Lu F., Yang Y.C., et al. Epidemiologic study of type 2 diabetes in Taiwan. Diabetes Res Clin Pract 2000, 50(Suppl 2):S49-S59.
3. Bureau of Health Promotion, Department of Health R.O.C Taiwan: November, 2003 Prevalence report of hypertension, hyperglycemia and hyperlipidemia in Taiwan Accessed March 30, 2011. http://www.bhp.doh.gov.tw/health91/study-2.htm.
4. Hu F.B., Stampfer M.J., Haffner S.M., et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129-1134.
5. Morrish N.J., Wang S.L., Stevens L.K., et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001, 44:14-21.
6. Fox C.S., Coady S., Sorlie P.D., et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007, 115:1544-1550.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Diabetes Study Group.
9. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358. Action to Control Cardiovascular Risk in Diabetes Study Group, 2545-2459.
10. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
11. Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374-381.
12. Wingard D.L., Barrett-Connor E. Heart disease and diabetes. Diabetes in America 1995, 429-448. National Institutes of Health, Bethesda, Md, (NIH publication no. 95-1468). 2nd ed. M.I. Harris (Ed.).
13. Deedwania P.C. Pharmacotherapy of hypertension in patients with diabetes mellitus. Expert Opin Pharmacother 2001, 2:1805-1816.
14. Zimmet P., Shaw J., Alberti K.G. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 2003, 20:693-702.
15. Berry C., Tardif J.C., Bourassa M.G. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol 2007, 49:631-642.
16. Delea T.E., Edelsberg J.S., Hagiwara M., et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003, 26:2983-2989.
17. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
18. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
19. Diamond G.A., Bax L., Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007, 147:578-581.
20. Lipscombe L.L., Gomes T., Lévesque L.E., et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007, 298:2634-2643.
21. FDA briefing information, AVANDIA (rosiglitazone maleate) tablets, for the July 13-14, 2010 Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Accessed November 2, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218493.pdf.
22. Summary minutes of the joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held on July 30, 2007 Accessed November 2, 2011. http://www.fda.gov/ohrms/dockets/ac/07/minutes/2007-4308m1-final.pdf.
23. Providing data of National Health Insurance 1999, Bureau of National Health Insurance, Department of Health, Department of Health, Taiwan, NHI publication No. 88041782.
24. Contents of National Health Insurance Research Database Accessed March 30, 2011. http://w3.nhri.org.tw/nhird/date_01.html.
25. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
26. Arauz-Pacheco C., Parrott M.A., Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002, 25:134-147.
27. Athyros V.G., Papageorgiou A.A., Athyrou V.V., et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002, 25:1198-1202.
28. Haffner S.M., Lehto S., Rönnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
29. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
30. Hsiao F.Y., Huang W.F., Wen Y.W., et al. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf 2009, 32:675-690.
31. Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189-1195.
32. Margolis D.J., Hoffstad O., Strom B.L. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008, 17:753-759.
33. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
34. Habib Z.A., Tzogias L., Havstad S.L., et al. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf 2009, 18:437-447.
35. Ziyadeh N., McAfee A.T., Koro C., et al. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin Ther 2009, 31:2665-2677.
36. Juurlink D.N., Gomes T., Lipscombe L.L., et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009, 339:b2942.
37. Chou C.C., Lee M.S., Ke C.H., Chung M.H. Prescription patterns of hypertension-National Health Insurance in Taiwan. J Chin Med Assoc 2004, 67:123-130.
38. Chou C.C., Hu K.Y., Wu N.R., et al. Changes in drug prescription utilization for diabetic and hypertensive outpatients after initiation of the National Health Insurance's Global Budget Program in Taiwan. Med Sci Monit 2008, 14:PH33-PH39.
39. Woo K.S., Nicholls M.G. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995, 40:141-144.
40. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
41. Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129-1136.
42. Kannel W.B., Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol 1972, 29:154-163.
43. Davies R.F., Goldberg A.D., Forman S., et al. Asymptomatic cardiac ischemia pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997, 95:2037-2043.